Clinical trials: Monoclonal Antibody
Lower Respiratory Tract Infection
Evaluate the Safety and Efficacy of Nirsevimab in Healthy Preterm and Term Infants in China
The purpose of this study is to evaluate the Safety and Efficacy of Nirsevimab, in Healthy Preterm and Term Infants in China
- Trial name
- CHIMES (NCT05110261)
- Testing
- Nirsevimab
- Where
- 30 sites in China
- Volunteers
- 800 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Non-Small Cell Lung Cancer
Gut Microbiota Reconstruction for NSCLC Immunotherapy
In this study, patients with locally advanced or metastatic NSCLC after first-line treatment with PD-1/PDL-1 monoclonal antibody will be treated with Gut Microbiota reconstruction(such as FMT) combined with PD-1/PDL-1 monoclonal…
- Trial name
- NCT05008861
- Testing
- Capsulized Fecal Microbiota Transplant, Anti-programmed cell death protein 1/programmed death-ligand 1 monoclonal antibody, Platinum based chemotherapy
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Shanghai Zhongshan Hospital
Multiple Myeloma
Phase 1/2 Study of Anti GM-2 Monoclonal Antibody To Treat Multiple Myeloma
This study will test the ability of a specially designed monoclonal antibody to destroy multiple myeloma cells. This antibody is unique in its ability to promote the death of multiple myeloma cells by processes known as antibody…
- Trial name
- NCT00775502
- Testing
- BIW-8962
- Where
- 5 sites in United States
- Volunteers
- 23 people
- Sponsor
- Kyowa Kirin Co., Ltd.
Solid Tumors
Methotrexate Combined With Immunotherapy During Radiotherapy for Solid Tumors
Immune checkpoint inhibitors, such as programmed death 1 (PD-1) and programmed cell death-Ligand 1 (PD-L1), offer new approaches for systemic treatment of tumors, but clinical efficacy remains limited.
- Trial name
- NCT05522582
- Testing
- Methotrexate tablets, Anti-PD-1 monoclonal antibody, Radiotherapy
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Yancheng First People's Hospital
Arthritis, Rheumatoid
A Study of CNTO 136 (Sirukumab), a Human Anti-IL-6 Monoclonal Antibody, Administered Subcutaneously, in Patients With Active Rheumatoid Arthritis Despite Anti-TNF-Alpha Therapy (SIRROUND-T)
The purpose of this study is to assess the efficacy of sirukumab as measured by the reduction of the signs and symptoms of rheumatoid arthritis (RA) in patients with active RA who are unresponsive or intolerant to treatment with…
- Trial name
- NCT01606761
- Testing
- Sirukumab
- Where
- 201 sites in United States, Argentina and 20 more
- Volunteers
- 878 people
- Sponsor
- Janssen Research & Development, LLC
Smoldering Multiple Myeloma, Monoclonal Gammopathy of Undetermined Significance
Screening to Improve Survival in AL Amyloidosis
The purpose of this study is to see whether certain genes may be linked with the development of AL amyloidosis in subjects 60 years of age or older with the blood disorders SMM and MGUS.
- Trial name
- NCT04615572
- Where
- 6 sites in United States
- Volunteers
- 35 people
- Sponsor
- Tufts Medical Center
Hairy Cell Leukemia
Randomized Phase II Trial of Rituximab With Either Pentostatin or Bendamustine for Multiply Relapsed or Refractory Hairy Cell Leukemia
Background: Researchers are attempting to develop new treatments for hairy cell leukemia (HCL) that has not responded well to or has recurred after standard HCL therapies.
- Trial name
- NCT01059786
- Testing
- Pentostatin, Rituximab, Bendamustine
- Where
- United States
- Volunteers
- 69 people
- Sponsor
- National Cancer Institute (NCI)
Giant Cell Arteritis (GCA)
Phase III Study of Efficacy and Safety of Secukinumab Versus Placebo, in Combination With Glucocorticoid Taper Regimen, in Patients With Giant Cell Arteritis (GCA)
This is a phase III study of efficacy and safety of secukinumab versus placebo, in combination with glucocorticoid taper regimen, in patients with giant cell arteritis (GCA)
- Trial name
- GCAptAIN (NCT04930094)
- Testing
- Secukinumab 300 mg, Secukinumab 150 mg
- Where
- 104 sites in United States, Argentina and 25 more
- Volunteers
- 354 people
- Sponsor
- Novartis Pharmaceuticals
Metastatic Colorectal Cancer
Sym004 vs Standard of Care in Subjects With Metastatic Colorectal Cancer
This is a Phase 2, open-label, randomized, 3-arm trial investigating the efficacy of two Sym004 doses (Arm A and Arm B) compared with a control group (Arm C) in subjects with metastatic colorectal cancer (mCRC) and acquired…
- Trial name
- NCT02083653
- Testing
- Sym004 (12 mg/kg), Sym004 (9/6 mg/kg), Best Supportive Care (BSC)
- Where
- 54 sites in United States, Austria and 8 more
- Volunteers
- 254 people
- Sponsor
- Symphogen A/S
HIV-1 Infection
Study to Assess Safety and Activity of Combination Therapy of VRC07-523LS and Vorinostat on HIV-infected Persons
Adult participants (18-64 years old) with HIV-1 Infection on ART with a CD4 T cell count ≥ 350 cells/mm3 and viral suppression for ≥ 24 months will be enrolled on this study.
- Trial name
- NCT03803605
- Testing
- VRC07-523LS, Vorinostat (VOR)
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- University of North Carolina, Chapel Hill
Hyperlipidemia
LAPLACE-TIMI 57: Low-density Lipoprotein Cholesterol (LDL-C) Assessment With PCSK9 monoclonaL Antibody Inhibition Combined With Statin thErapy
To evaluate the effect of 12 weeks of subcutaneous (SC) evolocumab (AMG 145) administered every 2 weeks (Q2W) or every 4 weeks (Q4W), compared with placebo, on percent change from baseline in LDL-C when used in addition to a…
- Trial name
- LAPLACE (NCT01380730)
- Testing
- Evolocumab
- Where
- 100 sites in United States, Canada and 3 more
- Volunteers
- 631 people
- Sponsor
- Amgen
Monoclonal Gammopathy, Smoldering Multiple Myeloma
Phase II Study of the CD38 Antibody Daratumumab in Patients With High-Risk MGUS and Low-Risk Smoldering Multiple Myeloma
This research study is studying a drug as a possible treatment for Monoclonal Gammopathy of Unknown Significance (MGUS) or Smoldering Multiple Myeloma (SMM). The drug involved in this study is: -Daratumumab
- Trial name
- NCT03236428
- Testing
- Daratumumab
- Where
- 6 sites in United States
- Volunteers
- 42 people
- Sponsor
- Dana-Farber Cancer Institute
Advanced Malignancies
A Study Evaluating the Safety, Tolerability, and Initial Efficacy of Recombinant Human Anti-T-cell Immunoreceptor With Ig and ITIM Domains (TIGIT) Monoclonal Antibody Injection (IBI939) in Subjects With Advanced Malignant Tumors
This is an open-label, dose escalation, Phase I study to evaluate the safety, tolerability, pharmacokinetics and efficacy of IBI939 in subjects with advanced malignancies
- Trial name
- NCT04353830
- Testing
- IBI939, IBI939+ Sintilimab
- Where
- China
- Volunteers
- 34 people
- Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
Cachexia, Pancreatic Neoplasms
A Study of the Safety and Effectiveness of Infliximab (Remicade) in Patients With Pancreatic Cancer Related Cachexia
The purpose of this study is to evaluate the effectiveness and safety of infliximab, the active ingredient in Remicade, for the treatment of cachexia in pancreatic cancer patients who are receiving chemotherapy with gemcitabine.
- Trial name
- NCT00060502
- Testing
- Infliximab; Gemcitabine
- Volunteers
- 73 people
- Sponsor
- Centocor, Inc.
Multicentric Castleman's Disease
A Study to Evaluate the Efficacy and Safety of CNTO328 Plus Best Supportive Care in Multicentric Castleman's Disease
The purpose of this study is to demonstrate that CNTO 328 when administered in combination with best supportive care (BSC) is superior to BSC in terms of durable tumor and symptomatic response (complete response or partial…
- Trial name
- NCT01024036
- Testing
- Siltuximab, Best Supportive Care (BSC)
- Where
- 56 sites in United States, Australia and 21 more
- Volunteers
- 79 people
- Sponsor
- Janssen Research & Development, LLC
Asthma
Clinical Trial of MG-K10 in Stage III of Moderate to Severe Asthma
A randomized, double-blind, placebo-controlled Phase III clinical trial on the efficacy and safety of MG-K10 humanized monoclonal antibody injection in adolescent and adult patients with moderate to severe asthma.
- Trial name
- NCT06837922
- Where
- China
- Volunteers
- 504 people
- Sponsor
- Shanghai Mabgeek Biotech.Co.Ltd
Covid19
Intramuscular and Intravenous VIR-7831 (Sotrovimab) for Mild/Moderate COVID-19.
The COMET-TAIL main study evaluated efficacy, safety, and tolerability of IM sotrovimab versus IV sotrovimab in high-risk patients for the treatment of mild/moderate COVID-19.
- Trial name
- NCT04913675
- Testing
- sotrovimab
- Where
- 50 sites in United States, France and 1 more
- Volunteers
- 1,065 people
- Sponsor
- Vir Biotechnology, Inc.
Multiple Myeloma
Using Mass Spectrometry (EasyM) Detecting Minimal Residual Disease (MRD) in Multiple Myeloma
The presence of minimal residual disease (MRD) is an important prognostic factor for multiple myeloma, while M-protein is a widely accepted biomarker used for multiple myeloma (MM) diagnose.
- Trial name
- NCT05536700
- Where
- China
- Volunteers
- 67 people, healthy volunteers welcome
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
Rheumatoid Arthritis, Polyarthritis
The Use of Anti-CD4 Monoclonal Antibody (mAb)-Fragment for the Imaging of Chronic Inflammation in Patients With Active Rheumatoid Arthritis
Rheumatoid arthritis (RA) is a disease with a large economic impact due to the long lasting disabling nature of the disease. Furthermore, diagnosis of the disease is difficult and only a scheme with different symptoms is used to…
- Conditions
- Rheumatoid Arthritis, Polyarthritis, Rheumatism, Autoimmune Disease
- Trial name
- NCT00372177
- Testing
- Fab-fragment of Anti-human CD4
- Where
- Germany
- Volunteers
- 5 people
- Sponsor
- Biotectid GmbH
Hepatocellular Carcinoma, Gastric Cancer
Combination of TATE and PD-1 Inhibitor in Liver Cancer
This is a multi-center, open-label phase IIA study that investigates the preliminary efficacy of Trans-arterial Tirapazamine Embolization (TATE) treatment of liver cancer followed by a PD-1 checkpoint inhibitor (nivolumab).
- Trial name
- TATE-PD1 (NCT03259867)
- Testing
- Nivolumab Injectable Product, Trans-arterial tirapazamine embolization
- Where
- 3 sites in United States
- Volunteers
- 54 people
- Sponsor
- Teclison Ltd.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.